Clinical Trials Logo

Ischemia clinical trials

View clinical trials related to Ischemia.

Filter by:

NCT ID: NCT03040063 Recruiting - Limb Ischemia Clinical Trials

Complex Endovascular Approach to Treatment of Patients With Aneurysm of Popliteal Artery

EVAR-P
Start date: August 1, 2016
Phase: N/A
Study type: Interventional

Use of endovascular techniques - implantation of a peripheral stent graft and a peripheral flexible stent to isolate the sac of the popliteal artery aneurysm from the circulation and subsequent topical application of a thrombolytic (rtPA) to restore patency of the lower leg blood stream - will lead to a comparable or better outcome in treatment of patients with the popliteal artery aneurysm and acute critical limb ischaemia, compared to currently prevailing use of surgical treatment.

NCT ID: NCT03034902 Terminated - Stroke Clinical Trials

Detection of Area of Ischemia in Patients With Subacute Stroke Via a Hybrid EEG-fNIRS Brain-computer Interface

Start date: February 9, 2017
Phase: N/A
Study type: Interventional

The purpose of this research study is to determine whether a combined electroencephalography (EEG) and functional near infrared spectroscopy (fNIRS) recording is able to detect changes in brain activity and blood flow after stroke.

NCT ID: NCT03032471 Terminated - Stroke Clinical Trials

Swiss SOS MoCA - DCI Study

Start date: July 20, 2017
Phase:
Study type: Observational

The primary objective of this multicenter observational study is to determine the effect size of the relationship between DCI and neuropsychological impairment 14-28 days and 3 months after aSAH. Secondary objectives are the feasibility to administer and the validity of the MoCA in an intensive care unit setting, as well as the test/retest reliability of the MoCA in patients with acute brain damage in absence of aSAH.

NCT ID: NCT03031470 Completed - Clinical trials for Early Allograft Dysfunction

Pilot Study of Reparixin for Early Allograft Dysfunction Prevention in Liver Transplantation

Start date: March 2015
Phase: Phase 2
Study type: Interventional

Liver transplantation is currently the treatment of choice for end-stage liver cirrhosis of different origin, as well as for a number of inborn metabolism disorders and liver tumors. The need to perform a liver transplantation is high and amounts to 10 - 20 patients per 1 million population per year. Experimental and clinical evidence demonstrate the harmful short and long-term effects of ischemia-reperfusion injury (IRI) of the donor organ on the outcome of the intervention performed. Severe manifestations of IRI of the liver transplant (LT) is one of the main reasons for the increased length of hospitalization, the high cost of treating patients during the post- surgery period, the development of persistent early allograft dysfunction or loss, frequent crises of acute rejection, acute renal and multiple organ failure, and mortality of the operated patients. This pilot clinical study is designed to evaluate the efficacy and safety of Reparixin, which is a new, potent and specific inhibitor of chemokine CXCL8 (Interleukin-8), as an agent to prevent early allograft dysfunction caused by ischemia-reperfusion injury in patients undergoing orthotopic liver transplantation.

NCT ID: NCT03030872 Completed - Ischemia Clinical Trials

Clinical Evaluation of CARESTREAM Vue PACS v12.2 MR Perfusion and Diffusion

Start date: January 7, 2017
Phase:
Study type: Observational

The objective of this study is to compare the diagnostic value of MR DSC-Perfusion (Perfusion Module), MR DWI (Diffusion Module) and MR DTI (Diffusion Module) in CARESTREAM Vue PACS ("investigational device") to the Olea Sphere PACS with Perfusion and DWI Modules ("predicate device"). Therefore, there will be several separate objectives depending on the type of acquisition:

NCT ID: NCT03027011 Recruiting - Brain Injuries Clinical Trials

Remote Ischemic Preconditioning on Brain Injury in Carotid Endarterectomy

Start date: March 1, 2017
Phase: N/A
Study type: Interventional

This is a randomized controlled trial designed to test an intervention (Remote ischemic preconditioning) in patients undergoing carotid endarterectomy (CEA).Remote ischemic preconditioning(RIPC) with transient upper limb ischemia/reperfusion is a novel, simple, cost-free,non-pharmacological and non-invasive strategy.The purpose of this study is to evaluate the effects of Remote Ischaemic Preconditioning on perioperative ischaemic injury in patients undergoing carotid endarterectomy compared to control intervention.The outcomes of interest include neurocognitive function,clinical outcomes,and biomarkers of brain injury.

NCT ID: NCT03024476 Completed - Hypertension Clinical Trials

Optimization of Blood Pressure Management After Acute Ischemic Stroke and Its Prognostic Significance

Start date: September 1, 2016
Phase: Phase 2
Study type: Interventional

BOSS-Trial I is a phase 2 clinical trial with the following objectives; 1. to prove the feasibility of a Bluetooth-equipped sphygmomanometer system in real-world clinical practice and wireless connection to the main server; 2. to prove the feasibility of the BP management strategy, including the pre-specified BP range, BP management algorithm, and behavioral; and 3. to gather information for the phase 3 trial including BP variability indices and their potentials as a treatment guidance.

NCT ID: NCT03023150 Completed - Clinical trials for Stroke Rehabilitation

Ischemic Preconditioning as an Intervention to Improve Stroke Rehabilitation - Froedtert

Start date: October 2016
Phase: N/A
Study type: Interventional

This study will be the first study to use ischemic preconditioning (IPC) as an intervention to improve stroke rehabilitation. IPC is a well studied, well tolerated intervention which has been shown to improve regional blood flow, motor neuron excitability and muscle function in multiple patient groups and in young, healthy subjects. Because IPC targets three physiological systems which are all affected by stroke, we hypothesize that repeated bouts of IPC during the first days to months following stroke (when the majority of recovery occurs) will make traditional rehabilitation strategies more effective.

NCT ID: NCT03016182 Recruiting - Lung Injury Clinical Trials

Remote Ischemic Preconditioning on Pulmonary Injury in Cardic Surgery

Start date: February 7, 2017
Phase: N/A
Study type: Interventional

During cardiac surgery with cardiopulmonary bypass , pulmonary dysfunction remains to be a problem complicating the postoperative course of the patients.Remote ischemic preconditioning(RIPC) with transient upper limb ischemia/reperfusion is a novel, simple, cost-free,non-pharmacological and non-invasive strategy.Recent several trials suggested that RIPC could provide pulmonary protection by reducing serum biomarkers,however,whether the RIPC can improve the clinical outcomes in patients undergoing on-pump cardiac surgery,is still uncertain. The study hypothesis is: remote ischemic preconditioning will provide lung-protective effect and improve clinical outcomes in patients undergoing cardic surgery.

NCT ID: NCT03010839 Completed - Myocardial Injury Clinical Trials

Cardiopulmonary Protective Effects of Modified Remote Ischaemic Preconditioning in Mitral Valve Replacement Surgery

Start date: November 5, 2016
Phase: N/A
Study type: Interventional

During cardiac surgery with cardiopulmonary bypass , injury occurs to the heart muscle and the lung.The heart and lung injury is a serious complication ,which increases both mortality and morbidity of cardiac surgery .Remote ischemic preconditioning(RIPC) with transient upper limb ischemia/reperfusion is a novel, simple, cost-free,non-pharmacological and non-invasive strategy.Recent some trials suggested that RIPC could provide myocardial protection by reducing serum cardiac biomarkers,however, more recent multicenter studies[9-11] had failed to show the protective effects of RIPC with respect to the troponin release and lung injury. Remote ischemic preconditioning (RIPC) is reported to have the early-phase and delayed-phase organ protective effects, whether the modified RIPC protocol induced repeatedly has the cardiopulmonary protective effect is still uncertain.